Article
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2012
Hildebrandt Michelle A T, Lippman Scott M, Etzel Carol J, Kim Edward, Lee J Jack, Khuri Fadlo R, Spitz Margaret R, Lotan Reuben, Hong Waun Ki, Wu Xifeng
Abstract excerpt
PURPOSE: The development of second primary tumors (SPT) or recurrence alters prognosis for curatively treated head and neck squamous cell carcinoma (HNSCC) patients. The 13-cis-Retinoic acid (13-cRA) has been tested as a chemoprevention agent in clinical trials with mixed results. Therefore, we investigated whether genetic variants in the PI3K/PTEN/AKT/mTOR pathway could serve as biomarkers to identify which...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
